Labcorp Perspectives Oncology: Tumor-agnostic therapies and the future of HER2 in oncology

The way we treat cancer is evolving in an exciting way, shifting from organ-specific approaches to therapies guided by molecular biology. In the latest episode of Labcorp Perspectives: Oncology, Dr. Rebecca Previs is joined by her colleague, Labcorp Director of Medical Affairs, Dr. Heidi Ko, a breast medical oncologist, to discuss one of the most exciting developments in precision oncology: tumor-agnostic therapies. Their conversation offers a timely and insightful look into how molecular profiling is changing treatment paradigms, and what this means for the future of cancer care.